Bio Gerrit Meijer is professor of pathology with a special interest in gastrointestinal oncology and translational research. After finishing medical school at the Vrije Universiteit Amsterdam he completed his PhD on “Cancer Risk Assessment in Adenoma Bearing Patients”. He had his training in pathology at the VU University Medical Center (VUmc) where he continued to work as a pathologist and from 2009 as chair of the Department of Pathology. Since March 2015 he is head of the Department of Pathology and Group leader at the Netherlands Cancer Institute/Antoni van Leeuwenhoek. Professor Meijer leads a translational research group that focuses on gastrointestinal cancer, especially biomarker development for early detection of colorectal cancer, as well as definition of molecular intermediate endpoints for screening. This work is a.o. funded by a Stand Up To Cancer & Dutch Cancer Society “Dream Team” grant for early detection of colorectal cancer. Next to that he is involved in the development of (inter-)national research infrastructures for biobanking and research IT, including the Dutch national personalized medicine & health research infrastructure Health-RI, BBMRI, EATRIS, tranSMART foundation as well as AACR GENIE. Gerrit Meijer has been and still is closely involved in the development, implementation and execution of the Dutch national colorectal cancer screening program, serving on several program committees. Title: AACR GENIE for sharing real life clinical and genomics data in oncology Abstract AACR Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE) is a multi-phase, multi-year, international data-sharing project that catalyzes precision oncology through the development of a regulatory-grade registry that aggregates and links clinical-grade cancer genomic data with clinical outcomes from tens of thousands of cancer patients treated at multiple international institutions. AACR Project GENIE fulfills an unmet need in oncology by providing the statistical power necessary to improve clinical decision-making, particularly in the case of rare cancers and rare variants in common cancers. Additionally, the registry will power novel clinical and translational research. The data within GENIE will ultimately be shared with the global research community after defined periods of time. The project will also serve as a prototype for aggregating, harmonizing, and sharing clinical-grade, next-generation sequencing data obtained during routine medical practice. The registry already contains more than 18,500 of the existing CLIA-/ISO- certified genomic data obtained during the course of routine practice at multiple international institutions, and will continue to grow as more patients are treated at the participating centers. As a result, the registry is derived from a variety of cancer types, including rare cancers, and will be enriched in examples of late-stage disease, providing a “real world” dataset. Additionally, the registry only contains primary data and is not dependent on the curation of the published literature. Finally, unlike some health IT platforms and other large-scale projects, GENIE does not seek to improve the quality of routine cancer care or to assign patients to clinical trials as primary objectives. The eight founding members of the consortium and phase 1 participants are: The Center for Personalized Cancer Treatment/NKI Utrecht/Amsterdam, Netherlands; Dana-Farber Cancer Institute, Boston; Institut Gustave Roussy, Villejuif, France; Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center, Baltimore; Memorial Sloan Kettering Cancer Center, New York; Princess Margaret Cancer Centre, Toronto; The University of Texas MD Anderson Cancer Center; and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.